{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:56:53Z","timestamp":1773295013587,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s12094-015-1345-4","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T06:28:10Z","timestamp":1436768890000},"page":"138-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pemetrexed for primary central nervous system lymphoma in the elderly"],"prefix":"10.1007","volume":"18","author":[{"given":"S.","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"key":"1345_CR1","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/cncr.10851","volume":"95","author":"JE Olson","year":"2002","unstructured":"Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95:1504\u201310.","journal-title":"Cancer"},{"key":"1345_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","volume":"58","author":"AJ Ferreri","year":"2002","unstructured":"Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58:1513\u201320.","journal-title":"Neurology"},{"key":"1345_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266\u201372.","journal-title":"J Clin Oncol"},{"key":"1345_CR4","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711\u20135.","journal-title":"J Clin Oncol"},{"key":"1345_CR5","unstructured":"CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004\u20132006. Hinsdale, IL: Central Brain Tumor Registry of the United States. 2010. www.cbtrus.org."},{"key":"1345_CR6","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","volume":"21","author":"K Hoang-Xuan","year":"2003","unstructured":"Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60\u00a0years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21:2726\u201331.","journal-title":"J Clin Oncol"},{"key":"1345_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/annonc\/mdi075","volume":"16","author":"K Jahnke","year":"2005","unstructured":"Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16:445\u20139.","journal-title":"Ann Oncol"},{"key":"1345_CR8","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","volume":"18","author":"LE Abrey","year":"2000","unstructured":"Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144\u201350.","journal-title":"J Clin Oncol"},{"key":"1345_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-007-9397-0","volume":"85","author":"AM Omuro","year":"2007","unstructured":"Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol. 2007;85:207\u201311.","journal-title":"J Neurooncol"},{"key":"1345_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","volume":"62","author":"AM Omuro","year":"2005","unstructured":"Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62:1595\u2013600.","journal-title":"Arch Neurol"},{"key":"1345_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00277-012-1441-2","volume":"91","author":"B Kasenda","year":"2012","unstructured":"Kasenda B, Rehberg M, Thurmann P, Franzem M, Veelken H, Fritsch K, et al. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. Ann Hematol. 2012;91:1257\u201364.","journal-title":"Ann Hematol"},{"key":"1345_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1215\/15228517-2008-067","volume":"11","author":"JJ Zhu","year":"2009","unstructured":"Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11:211\u20135.","journal-title":"Neuro Oncol"},{"key":"1345_CR13","first-page":"1116","volume":"57","author":"C Shih","year":"1997","unstructured":"Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116\u201323.","journal-title":"Cancer Res"},{"key":"1345_CR14","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/cncr.26709","volume":"118","author":"JJ Raizer","year":"2012","unstructured":"Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, et al. Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma. Cancer. 2012;118:3743\u20138.","journal-title":"Cancer"},{"key":"1345_CR15","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","volume":"22","author":"K Fritsch","year":"2011","unstructured":"Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22:2080\u20135.","journal-title":"Ann Oncol"},{"key":"1345_CR16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/cncr.22907","volume":"110","author":"KS Panageas","year":"2007","unstructured":"Panageas KS, Elkin EB, Ben-Porat L, Deangelis LM, Abrey LE. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer. 2007;110:1338\u201344.","journal-title":"Cancer"},{"key":"1345_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","volume":"23","author":"DF Nelson","year":"1992","unstructured":"Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9\u201317.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1345_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/annonc\/mdn628","volume":"20","author":"G Illerhaus","year":"2009","unstructured":"Illerhaus G, Marks R, Muller F, Ihorst G, Feuerhake F, Deckert M, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319\u201325.","journal-title":"Ann Oncol"},{"key":"1345_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1215\/15228517-2-1-40","volume":"2","author":"S Ng","year":"2000","unstructured":"Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol. 2000;2:40\u20134.","journal-title":"Neuro Oncol"},{"key":"1345_CR20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e318266fcb2","volume":"79","author":"P Roth","year":"2012","unstructured":"Roth P, Martus P, Kiewe P, Mohle R, Klasen H, Rauch M, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012;79:890\u20136.","journal-title":"Neurology"},{"key":"1345_CR21","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/neuonc\/nos207","volume":"14","author":"MR Welch","year":"2012","unstructured":"Welch MR, Omuro A, Deangelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol. 2012;14:1304\u201311.","journal-title":"Neuro Oncol."},{"key":"1345_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11060-009-0032-0","volume":"97","author":"D Kurzwelly","year":"2010","unstructured":"Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol. 2010;97:389\u201392.","journal-title":"J Neurooncol"},{"key":"1345_CR23","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ajh.23812","volume":"89","author":"G Olivier","year":"2014","unstructured":"Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A, et al. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol. 2014;89:1024\u20139.","journal-title":"Am J Hematol"},{"key":"1345_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000363435","volume":"37","author":"SY Lee","year":"2014","unstructured":"Lee SY, Okoshi Y, Kurita N, Seki M, Yokoyama Y, Maie K, et al. Prognosis factors in Japanese elderly patients with primary central nervous system lymphoma treated with a nonradiation, intermediate-dose methotrexate-containing regimen. Oncol Res Treat. 2014;37:378\u201383.","journal-title":"Oncol Res Treat"},{"key":"1345_CR25","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1002\/cncr.25363","volume":"116","author":"DE Ney","year":"2010","unstructured":"Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 2010;116:4605\u201312.","journal-title":"Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1345-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-015-1345-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1345-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1345-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:56:28Z","timestamp":1659095788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-015-1345-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1007\/s12094-015-1345-4","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]},"assertion":[{"value":"4 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}